Radiopharm Theranostics (ASX:RAD) has announced that Imperial College London has released additional data related to the F-18 Pivalate (RAD 101) Phase 2a imaging trial in patients with brain metastases.
The company said that high-contrast images were seen at 60 minutes after radiotracer injection.
The images showed the maximum standardised uptake within lesions compared to the mean differed in a statistically significant manner.
The calculated 'Tumour-to-Background' ratio ranged from 1.73 to 6.07. The company said this supports the assertion of high image contrast in patients regardless of the origin of the primary cancer.
Radiopharm said the initial data announced on 18 October showed significant tumour uptake that was consistent and independent from the tumour origin. It also indicated that Pivalate can be used to monitor cerebral metastases.
“The new data released shows the additional benefit of PET scan with F-18 Pivalate in detecting the metabolic activity in the brain metastases,” said CEO Riccardo Canevari.
“This quality image is a promising indication that the tracer can be used to monitor brain metastases, which is yet another positive step for the potential of this technology for Radiopharm.”